Table 6.
Sensitivity and specificity analyses for Gleason score (4+4) downgrade
| Characteristics | No downgrade, n (%) | Downgraded, n (%) | P | Sensitivity (%) | Specificity (%) | Correctly classify (%) | ROC area |
|---|---|---|---|---|---|---|---|
| Core+ ≤1 | 0.011* | 80.4 | 44.4 | 62.6 | 0.62 | ||
| No | 20 (69.0) | 9 (31.0) | |||||
| Yes | 25 (40.3) | 37 (59.7) | |||||
| Percentage of tumor in maximum core+ ≤16.7% | 0.008* | 84.8 | 40.0 | 62.6 | 0.62 | ||
| No | 18 (72.0) | 7 (28.0) | |||||
| Yes | 27 (40.9) | 39 (59.1) | |||||
| Maximum core+ length ≤5 mm | 0.145 | 78.3 | 35.6 | 57.1 | 0.57 | ||
| No | 16 (61.5) | 10 (38.5) | |||||
| Yes | 29 (44.6) | 36 (55.4) | |||||
| Percentage of PCa in total specimen ≤12% | 0.799 | 59.2 | 43.2 | 51.2 | 0.51 | ||
| No | 19 (52.8) | 17 (47.2) | |||||
| Yes | 25 (50.0) | 25 (50.0) | |||||
| Age ≤65 years | 0.731 | 41.3 | 62.2 | 51.7 | 0.52 | ||
| No | 28 (50.9) | 27 (49.1) | |||||
| Yes | 17 (47.2) | 19 (52.8) | |||||
| PSA ≤6.05 ng ml−1 | 0.342 | 52.2 | 57.8 | 55.0 | 0.55 | ||
| No | 26 (54.2) | 22 (45.8) | |||||
| Yes | 19 (44.2) | 24 (55.8) | |||||
| PSAD ≤0.20 ng ml−1 | 0.241 | 63.2 | 50.0 | 56.4 | 0.57 | ||
| No | 20 (58.8) | 14 (41.2) | |||||
| Yes | 20 (45.5) | 24 (54.5) | |||||
| Total number of biopsy cores ≤6 | 0.964 | 15.2 | 84.4 | 49.5 | 0.50 | ||
| No | 38 (49.4) | 39 (50.6) | |||||
| Yes | 7 (50.0) | 7 (50.0) |
*P<0.05 was considered statistically significant. PCa: prostate cancer; PSA: prostate-specific antigen; PSAD: prostate-specific antigen density; ROC: receiver operating characteristic